

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

诺诚健华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9969)

2026 QUARTERLY REPORT FOR THE FIRST QUARTER

This announcement is made by InnoCare Pharma Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

2026 QUARTERLY REPORT FOR THE FIRST QUARTER

Reference is made to the “InnoCare Pharma Limited 2026 First Quarterly Report” (the “**2026 First Quarterly Report**”) published by the Company on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the 2026 First Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version shall prevail.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited, have been reviewed by the audit committee of the Company, but have not been reviewed by the independent auditors of the Company.

The unaudited financial data in the 2026 First Quarterly Report set out in this announcement is prepared in accordance with the accounting principles of the People’s Republic of China instead of the International Financial Reporting Standards, and are prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only.

Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 23 April 2026

As at the date of this announcement, the Board comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi and Mr. Ronggang Xie as non-executive Directors, and Ms. Lan Hu, Dr. Dandan Dong and Prof. Kunliang Guan as independent non-executive Directors.

Stock Code: 688428

Ticker Symbol: InnoCare

InnoCare Pharma Limited

2026 FIRST QUARTERLY REPORT

The board of directors and all directors of the Company affirm that this announcement contains no false records or misleading statements or material omissions and that they are responsible for the truthfulness, accuracy, and completeness of its contents in accordance with the laws.

IMPORTANT NOTICE

The board of directors, directors and senior management of the Company undertake that the contents of the quarterly report are true, accurate, complete and without any false records, misleading statements or material omissions and are severally and jointly liable therefor.

The person in charge of the Company, person in charge of accounting function and person in charge of the Accounting Department (chief accounting officer) warrant the truthfulness, accuracy and completeness of the financial information contained in the quarterly report.

Whether the first quarterly financial statements have been audited

Yes No

MANAGEMENT PERFORMANCE REVIEW

The management of InnoCare Pharma Limited (the “Company”) commented, “The Company is a high-tech innovative biopharmaceutical enterprise driven by outstanding independent research and development capabilities, possessing comprehensive research and development, manufacturing and commercialization abilities. It focuses on areas with significant unmet clinical needs such as oncology and autoimmune diseases, developing drugs with breakthrough potential that are either first-in-class or best-in-class on a global scale.

From January to March 2026, the Company’s revenue from sales of drugs reached RMB450 million, representing an increase of 44.54% as compared to the same period last year, total operating revenue

reached RMB529 million, representing an increase of 38.65% as compared to the same period last year. The increase in operating revenue was primarily driven by continued volume growth of the core product orelabrutinib, new contributions from tafasitamab and zurletrectinib, and the achievement of subsequent milestone payments under the license agreement between the Company and Zenas BioPharma, Inc. (“Zenas”). From January to March 2026, net profit of the Company reached RMB102 million, representing an increase of 607.72% as compared to the same period last year. With a mature commercialization system and a research and development pipeline progressing smoothly, the Company is poised to maintain high-quality growth in the future.

As of 31 March 2026, the Company held cash and related accounts balance totalling approximately RMB7.921 billion. This balance consists of cash and bank balances, as well as financial assets recorded under financial assets held for trading, other current assets, non-current assets due within one year and other non-current assets.

With sufficient cash reserves, the Company will continue to accelerate the development of various pipeline projects in an effort to provide more and better treatment options for patients in China and around the world.”

I. KEY FINANCIAL INFORMATION

(I) Key accounting data and financial indicators

Unit: RMB Currency: Renminbi

Items	The reporting period	Same period of last year	Increase/decrease during the reporting period compared with the same period of last year (%)
Operating revenue	528,625,471.80	381,263,139.35	38.65
Among which: revenue from sales of drugs	450,496,892.18	311,666,494.52	44.54
Total profit	104,848,605.76	16,394,050.53	539.55
Net profit attributable to shareholders of the listed company	105,817,401.83	17,967,628.89	488.93
Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses	95,929,620.54	1,591,658.29	5,927.02
Net cash flows generated from operating activities	4,219,970.54	56,524,292.65	-92.53
Basic earnings per share (RMB/share)	0.06	0.01	500.00

InnoCare Pharma Limited 2026 FIRST QUARTERLY REPORT

Diluted earnings per share (RMB/share)	0.06	0.01	500.00
Weighted average return on equity (%)	1.40	0.27	Increase of 1.13 percentage points
Total R&D expenditure	229,155,824.80	207,599,189.43	10.38
R&D expenditure as a percentage of operating revenue (%)	43.35	54.45	Decrease of 11.10 percentage points
	As at the end of the reporting period	As at the end of the last year	Increase/decrease as at the end of the reporting period compared with the end of last year (%)
Total assets	10,383,127,314.67	10,823,600,850.70	-4.07
Owners' equity attributable to shareholders of the listed company	7,344,213,267.12	7,726,823,182.19	-4.95

(II) Non-recurring profits and losses items and amounts

Applicable Not applicable

Unit: RMB Currency: Renminbi

Non-recurring profits and losses items	Amount for the reporting period	Description
Government grants included in current profits and losses (excluding those closely related to the Company's normal course of business operations, in compliance with national policies and regulations, and have a continuous impact on the Company's profit or loss according to established standards)	1,211,085.08	
Profits and losses arising from changes in fair value of financial assets and financial liabilities held by a non-financial enterprise, and profits and losses arising from disposal of financial assets and financial liabilities, except for effective hedging business related to the Company's normal operations	9,327,406.70	
Other non-operating income and expenses other than the above items	325,037.77	
Less: Effect on income tax	-965,248.26	
Effect on minority interests (after tax)	-10,500.00	
Total	9,887,781.29	

Reasons should be provided for identifying items not listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and Losses" as non-recurring profit or loss items with significant amounts, as well as for defining the non-recurring profit or loss items set out in the "Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and Losses" as recurring profit or loss items.

Applicable Not applicable

(III) Changes in key accounting data and financial indicators and the reasons therefor

√Applicable Not applicable

Item	Percentage change (%)	Main reason
Operating revenue	38.65	Significant increase in operating revenue for the period was primarily due to continued growth in revenue from sales of drugs and the completion of subsequent milestone payments under the license agreement between the Company and Zenas
Among which: revenue from sales of drugs	44.54	
Total profit	539.55	Profit for the period increased significantly as compared to the same period last year, primarily due to continued growth in revenue from sales of drugs and the completion of subsequent milestone payments under the license agreement between the Company and Zenas
Net profit attributable to shareholders of the listed company	488.93	
Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses	5,927.02	
Basic earnings per share (RMB/share)	500.00	
Diluted earnings per share (RMB/share)	500.00	
R&D expenditure as a percentage of operating revenue (%)	Decrease of 11.10 percentage points	This was primarily due to the significant increase in operating revenue for the period
Net cash flows generated from operating activities	-92.53	This was primarily due to an increase in cash expenditures related to production and R&D for the period, as well as higher tax payments

II. SHAREHOLDER INFORMATION

1. As of the end of the reporting period, the total number of issued shares of the Company was 1,764,643,952 shares, of which 1,496,284,235 shares were issued in Hong Kong, representing approximately 84.79% of the total issued shares of the Company. The number of RMB shares issued on the SSE STAR Market was 268,359,717 shares, representing approximately 15.21% of the total issued shares of the Company.

2. The Hong Kong register of members of the Company consists of HKSCC NOMINEES LIMITED (HKSCC Nominees Limited) and other registered shareholders, of which HKSCC NOMINEES LIMITED held approximately 99.999% of the Company's Hong Kong shares on behalf of non-registered shareholders, and approximately 0.001% of the Company's Hong Kong shares were held by other registered shareholders.

3. Shares held by HKSCC NOMINEES LIMITED are held on behalf of various customers. According to the relevant shareholder equity disclosure rules of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, shareholders holding 5% or more of the shares are required to disclose their shareholdings, while shareholders holding less than 5% are not required to proactively disclose their shareholdings. The Company is unable to obtain the names and shareholding percentages of overseas shareholders holding less than 5% through public channels. Thus, the table below presents the shares held by HKSCC NOMINEES LIMITED after excluding the shares held by HHLR Fund, L.P.

and its persons acting in concert, Sunny View Holdings Limited and the family of Renbin Zhao, Sunland BioMed Ltd and the family of Jisong Cui, respectively based on the disclosure information in declaration submitted by shareholders on the Hong Kong Stock Exchange as of the end of the reporting period.

4. As of the end of the reporting period, the shareholdings of the top ten shareholders are listed based on the disclosure information in declaration submitted by the relevant shareholders to the Hong Kong Stock Exchange and the A share register provided by CSDC. The nature of A shareholders is reported in accordance with the categories of holders in the A share register of CSDC.

(I) Total number of ordinary shareholders and the number of preferred shareholders whose voting rights have been restored, and shareholdings of the top ten shareholders

Unit: share

Total number of ordinary shareholders as at the end of the reporting period		20,621	Total number of preferred shareholders whose voting rights have been restored as at the end of the reporting period (if any)		-		
Shareholdings of the top ten shareholders (excluding lending shares for refinancing)							
Name of shareholder	Nature of shareholder	Number of shares held	Percentage of shareholding (%)	Number of restricted shares held	Number of restricted shares (including lending shares for refinancing)	Pledged, marked or frozen	
						Status of shares	Number of shares
HKSCC NOMINEES LIMITED	Unknown	1,013,282,187	57.4213	-	-	Unknown	-
HHLR Fund, L.P. and its persons acting in concert	Overseas legal person	208,671,222	11.8251	-	-	Unknown	-
Sunny View Holdings Limited and the family of Renbin Zhao	Overseas legal person	144,817,893	8.2066	-	-	Nil	-
	Overseas natural person						
Sunland BioMed Ltd and the family of Jisong Cui	Overseas legal person	127,012,782	7.1976	-	-	Nil	-
	Overseas natural person						
China Construction Bank Corporation - Fullgoal Precision Medicine Flexible Allocation Hybrid Securities Investment Fund	Others	12,154,925	0.6888	-	-	Nil	-
Xiaofa Chen	Domestic natural person	7,834,093	0.4439	-	-	Nil	-
Genlong Luo	Domestic natural person	4,995,654	0.2831	-	-	Nil	-

InnoCare Pharma Limited 2026 FIRST QUARTERLY REPORT

China Merchants Bank Co., Ltd. – Huitianfu Healthcare Service Flexible Allocation Hybrid Securities Investment Fund	Others	4,678,210	0.2651	-	-	Nil	-
China Merchants Bank Co., Ltd. – Dongfanghong Medical Upgrade Equity Initiated Securities Investment Fund	Others	3,838,143	0.2175	-	-	Nil	-
China Construction Bank Corporation - Baoying Healthcare Shanghai-Hong Kong-Shenzhen Equity Securities Investment Fund	Others	3,765,581	0.2134	-	-	Nil	-
Shareholdings of the top ten unrestricted shareholders (excluding lending shares for refinancing)							
Name of shareholder	Number of unrestricted outstanding shares held			Type and number of shares			
				Type	Number		
HKSCC NOMINEES LIMITED	1,013,282,187			Others	1,013,282,187		
HHLR Fund, L.P. and its persons acting in concert	208,671,222			Others	208,671,222		
Sunny View Holdings Limited and the family Renbin Zhao	144,817,893			Others	144,817,893		
Sunland BioMed Ltd and the family of Jisong Cui	127,012,782			Others	127,012,782		
China Construction Bank Corporation - Fullgoal Precision Medicine Flexible Allocation Hybrid Securities Investment Fund	12,154,925			RMB-denominated ordinary shares	12,154,925		
Xiaofa Chen	7,834,093			RMB-denominated ordinary shares	7,834,093		
Genlong Luo	4,995,654			RMB-denominated ordinary shares	4,995,654		
China Merchants Bank Co., Ltd. – Huitianfu Healthcare Service Flexible Allocation Hybrid Securities Investment Fund	4,678,210			RMB-denominated ordinary shares	4,678,210		
China Merchants Bank Co., Ltd. – Dongfanghong Medical Upgrade Equity Initiated Securities Investment Fund	3,838,143			RMB-denominated ordinary shares	3,838,143		
China Construction Bank Corporation - Baoying Healthcare Shanghai-Hong Kong-Shenzhen Equity Securities Investment Fund	3,765,581			RMB-denominated ordinary shares	3,765,581		
Description of the connected relationships among, or concerted actions taken by the above shareholders	The Company is not aware of whether the above other shareholders have other related relationships or concerted action relationships						

Description of the top ten shareholders and the top ten unrestricted shareholders involved in margin financing and securities lending and refinancing businesses (if any)	Nil
---	-----

Involvement of shareholders with shareholdings of more than 5%, top ten shareholders and top ten unrestricted shareholders in lending shares for refinancing businesses

Applicable Not applicable

Changes of top ten shareholders and top ten unrestricted shareholders as compared with the previous period due to lending/returning shares for refinancing

Applicable Not applicable

III. OTHER REMINDERS

Other important information about the operation of the Company during the reporting period to which investors should pay attention

Applicable Not applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Types of audit opinions

Applicable Not applicable

(II) Financial statements

Consolidated balance sheet

31 March 2026

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	March 31, 2026	December 31, 2025
Current assets:		
Cash and bank balances	6,188,959,800.83	7,072,287,570.25
Financial assets held for trading	902,841,466.80	-
Accounts receivable	488,391,549.34	502,876,484.30
Prepayments	76,258,806.57	55,363,555.79
Other receivables	622,806.09	1,023,083.75
Inventories	174,133,101.78	162,869,393.59
Non-current assets due within one year	54,275,410.34	108,266,458.00
Other current assets	310,704,193.95	159,435,900.95
Total current assets	8,196,187,135.70	8,062,122,446.63
Non-current assets:		
Long-term equity investments	2,174,400.98	2,704,223.73
Investments in other equity instruments	622,261,642.00	1,173,992,348.80
Other non-current financial assets	24,802,834.88	24,802,834.88
Fixed assets	572,282,669.67	588,282,163.13
Construction in progress	114,324,799.02	115,012,520.68
Right-of-use assets	42,860,733.42	48,964,579.34
Intangible assets	247,686,785.30	248,045,487.72
Goodwill	3,124,706.56	3,124,706.56
Long-term prepaid expenses	29,527,806.98	30,308,238.85
Other non-current assets	527,893,800.16	526,241,300.38
Total non-current assets	2,186,940,178.97	2,761,478,404.07
Total assets	10,383,127,314.67	10,823,600,850.70
Current liabilities:		
Short-term borrowings	388,289,014.28	176,927,924.31
Accounts payable	210,553,124.38	183,698,728.28
Contract liabilities	34,597,000.00	105,432,000.00
Payroll payable	39,575,549.26	78,488,891.35
Taxes payable	58,380,633.39	78,948,938.93
Other payables	104,572,551.04	144,425,839.99

InnoCare Pharma Limited 2026 FIRST QUARTERLY REPORT

Non-current liabilities due within one year	138,406,030.34	139,496,159.55
Other current liabilities	476,336,000.00	476,336,000.00
Total current liabilities	1,450,709,902.69	1,383,754,482.41
Non-current liabilities:		
Long-term borrowings	988,000,000.00	1,001,700,000.00
Lease liabilities	17,496,652.53	19,026,136.31
Long-term payables	278,145,498.38	274,015,713.79
Deferred income	285,583,598.76	289,422,538.71
Deferred income tax liabilities	-	106,509,409.61
Total non-current liabilities	1,569,225,749.67	1,690,673,798.42
Total liabilities	3,019,935,652.36	3,074,428,280.83
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	23,494.45	23,493.75
Capital reserve	12,218,840,312.84	12,199,116,468.68
Less: Treasury shares	19,753,678.96	19,753,678.96
Other comprehensive income	-83,027,805.11	425,123,356.65
Retained earnings	-4,771,869,056.10	-4,877,686,457.93
Total equity attributable to owners (or shareholders) of the parent company	7,344,213,267.12	7,726,823,182.19
Minority interests	18,978,395.19	22,349,387.68
Total owners' equity (or shareholders' equity)	7,363,191,662.31	7,749,172,569.87
Total liabilities and owners' equity (or shareholders' equity)	10,383,127,314.67	10,823,600,850.70

Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu

Person in charge of the Accounting Department: Yue Tan

Consolidated Statement of Income

January-March 2026

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	First Quarter in 2026	First Quarter in 2025
I. Total operating revenue	528,625,471.80	381,263,139.35
Including: Operating revenue	528,625,471.80	381,263,139.35
II. Total operating costs	438,101,958.81	383,940,887.34
Including: Operating costs	62,721,236.77	36,066,440.09
Taxes and surcharges	5,740,501.84	6,989,137.10
Selling expenses	118,800,688.11	114,012,126.98
Administrative expenses	43,647,054.33	42,762,733.27
R&D expenses	229,155,824.80	207,599,189.43
Finance costs	-21,963,347.04	-23,488,739.53
Including: Interest expenses	14,382,887.54	13,518,113.67

InnoCare Pharma Limited 2026 FIRST QUARTERLY REPORT

Interest income	25,216,546.70	33,751,558.37
Add: Other income	6,061,068.66	5,912,441.49
Investment income (loss denoted by “-”)	5,469,817.76	10,544,273.33
Including: Share of profit of associates and joint ventures	-529,822.75	78,944.71
Gain from changes in fair value (loss denoted by “-”)	3,327,766.19	2,560,936.02
Credit impairment loss (loss denoted by “-”)	-814,646.69	239,188.28
Impairment loss of assets (loss denoted by “-”)	-43,950.92	-188,438.83
Gain from disposal of assets (loss denoted by “-”)	-	3,398.23
III. Operating profit (loss denoted by “-”)	104,523,567.99	16,394,050.53
Add: Non-operating income	330,895.88	-
Less: Non-operating expenses	5,858.11	-
IV. Total profit (total loss denoted by “-”)	104,848,605.76	16,394,050.53
Less: Income tax expenses	2,402,196.42	1,918,575.70
V. Net profit (net loss denoted by “-”)	102,446,409.34	14,475,474.83
(I) By continuity of operations		
1. Net profit from continuing operations (net loss denoted by “-”)	102,446,409.34	14,475,474.83
(II) By attribution of ownership		
1. Net profit attributable to shareholders of the parent company (net loss denoted by “-”)	105,817,401.83	17,967,628.89
2. Profit or loss attributable to minority shareholders (net loss denoted by “-”)	-3,370,992.49	-3,492,154.06
VI. Other comprehensive income, net of tax	-508,151,161.76	-6,625,303.26
(I) Other comprehensive income attributable to owners of the parent company, net of tax		
1. Other comprehensive income not to be reclassified to profit or loss	-508,151,161.76	-6,625,303.26
(1) Translation differences of the financial statements in foreign currency	-73,308,369.07	-6,625,303.26
(2) Changes in the fair value of investments in other equity instruments	-434,842,792.69	-
VII. Total comprehensive income	-405,704,752.42	7,850,171.57
(I) Total comprehensive income attributable to owners of the parent company	-402,333,759.93	11,342,325.63
(II) Total comprehensive income	-3,370,992.49	-3,492,154.06

InnoCare Pharma Limited 2026 FIRST QUARTERLY REPORT

attributable to minority shareholders		
VIII. Earnings per share:		
(I) Basic earnings per share (RMB/share)	0.06	0.01
(II) Diluted earnings per share (RMB/share)	0.06	0.01

For business combinations under the same control in the current period, the net profit achieved by the parties consolidated prior to the consolidation was RMB0.00; the net profit achieved by the parties consolidated in the previous period was RMB0.00.

Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu
 Person in charge of the Accounting Department: Yue Tan

Consolidated Statement of Cash Flows

January-March 2026

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	First Quarter in 2026	First Quarter in 2025
I. Cash flows generated from operating activities:		
Cash receipts from sales of goods and provision of services	513,280,135.67	417,205,824.01
Cash received from other operating activities	12,250,536.24	30,398,876.74
Sub-total of cash inflows from operating activities	525,530,671.91	447,604,700.75
Cash paid for goods and services	218,334,866.23	145,285,952.64
Cash paid to and on behalf of employees	211,670,171.29	173,484,298.83
Cash paid for taxes and levies	84,387,218.53	35,333,690.31
Cash paid for other operating activities	6,918,445.32	36,976,466.32
Sub-total of cash outflows from operating activities	521,310,701.37	391,080,408.10
Net cash flows generated from operating activities	4,219,970.54	56,524,292.65
II. Cash flows generated from investment activities:		
Cash received from the disposal of investments	1,362,069,245.32	1,401,285,200.00
Cash received from investment income	11,630,806.71	16,054,993.70
Sub-total of cash inflows from investment activities	1,373,700,052.03	1,417,340,193.70
Cash paid for acquisition of fixed	20,036,058.88	15,058,034.49

InnoCare Pharma Limited 2026 FIRST QUARTERLY REPORT

assets, intangible assets and other long-term assets		
Cash paid for investments	1,860,505,000.00	1,324,058,800.00
Sub-total of cash outflows from investment activities	1,880,541,058.88	1,339,116,834.49
Net cash flows generated from investing activities	-506,841,006.85	78,223,359.21
III. Cash flows generated from financing activities:		
Cash received from capital contributions	1,191,488.99	303,955.42
Cash received from borrowings	372,474,104.41	79,200,000.00
Cash received from other financing activities	-	86,420,746.40
Sub-total of cash inflows from financing activities	373,665,593.40	165,924,701.82
Cash paid for repayment of debts	174,969,652.31	110,920,746.40
Cash paid for distribution of dividends or profits or settlement of interest	8,895,630.37	8,175,035.27
Cash paid for other financing activities	6,483,835.42	14,075,083.07
Sub-total of cash outflows from financing activities	190,349,118.10	133,170,864.74
Net cash flows generated from financing activities	183,316,475.30	32,753,837.08
IV. Effects of changes in exchange rate on cash and cash equivalents	-61,899,142.89	-3,257,880.35
V. Net increase in cash and cash equivalents	-381,203,703.90	164,243,608.59
Add: Balance of cash and cash equivalents at the beginning of the period	4,506,418,701.18	4,679,466,477.13
VI. Balance of cash and cash equivalents at the end of the period	4,125,214,997.28	4,843,710,085.72

Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu
 Person in charge of the Accounting Department: Yue Tan

Adjustment of the financial statements for the beginning of 2026 when the Company implements the new accounting standards or interpretation of standards for the first time

Applicable Not applicable

The announcement is hereby made.

Board of directors of InnoCare Pharma Limited
23 April 2026